Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever

International Journal of Infectious Diseases

Volumn 14, Issue 8, 2010, Pages

  Bodur, Hürrem ^a   Akinci, Esragül ^a   Öngürü, Pinar ^a   Uyar, Yavuz ^b   Baştürk, Bilkay ^c   Gözel, Mustafa Gökhan ^a   Kayaaslan, Bircan Ünal ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Refik Saydam Hifzissihha Merkezi   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

Adhesion molecules; Crimean Congo hemorrhagic fever; MIF; VEGF

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; PADGEM PROTEIN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN; ISOMERASE; MIF PROTEIN, HUMAN; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CASE CONTROL STUDY; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM; BLOOD; MIDDLE AGED; MORTALITY; NAIROVIRUS; PATHOGENICITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SURVIVAL; TURKEY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TURKEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77954953463     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.02.2240     Document Type: Article

References (29)

1. Whitehouse C.A. Crimean-Congo hemorrhagic fever. Antiviral Res 2004, 64:145-160.
2. Burt F.J., Leman P.A., Smith J.F., Swanepoel R. The use of a reverse transcription-polymerase chain reaction for the detection of viral nucleic acid in the diagnosis of Crimean-Congo haemorrhagic fever. J Virol Methods 1998, 70:129-137.
3. Centers for Disease Control and Prevention (CDC). Viral hemorrhagic fever: initial management of suspected and confirmed cases. MMWR Morb Mortal Wkly Rep 1983; 32:27S-38S.
4. Charrel R.N., Attoui H., Butenko A.M., Clegg J.C., Deubel V., Frolova T.V., et al. Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect 2004, 10:1040-1055.
5. Bakir M., Ugurlu M., Dokuzoguz B., Bodur H., Tasyaran M.A., Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005, 54:385-389. Turkish CCHF Study Group.
6. Schnittler H.J., Feldmann H. Viral hemorrhagic fever-a vascular disease?. Thromb Haemost 2003, 89:967-972.
7. Yapar M., Aydogan H., Pahsa A., Besirbellioglu B.A., Bodur H., Basustaoglu A.C., et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse transcriptase-PCR. Jpn J Infect Dis 2005, 58:358-362.
8. Cevik M.A., Erbay A., Bodur H., Gülderen E., Baştuĝ A., Kubar A., Akinci E. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008, 12:374-379.
9. Karti S.S., Odabasi Z., Korten V., Yilmaz M., Sonmez M., Caylan R., et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004, 10:1379-1384.
10. Ergonul O., Tuncbilek S., Baykam N., Celikbas A., Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006, 193:941-944.
11. Papa A., Bino S., Velo E., Harxhi A., Kota M., Antoniadis A. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol 2006, 36:272-276.
12. Onguru P., Akgul E.O., Akinci E., Yaman H., Kurt Y.G., Erbay A., et al. High serum levels of neopterin in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. J Infect 2008, 56:366-370.
13. Cevik M.A., Erbay A., Bodur H., Eren S.S., Akinci E., Sener K., et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis 2007, 45:e96-100.
14. Akinci E., Yilmaz M., Bodur H., Ongürü P., Bayazit F.N., Erbay A., Ozet G. Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2009, 13:560-563.
15. Weber F., Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zoonosis. Cytokine Growth Factor Rev 2008, 19:395-404.
16. Bevilacqua M.P., Nelson R.M., Mannori G., Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994, 45:361-378.
17. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993, 11:767-804.
18. Murgue B., Cassar O., Deparis X. Plasma concentrations of sVCAM-1 and severity of dengue infections. J Med Virol 2001, 65:97-104.
19. Khongphatthanayothin A., Phumaphuti P., Thongchaiprasit K., Poovorawan Y. Serum levels of sICAM-1 and sE-selectin in patients with dengue virus infection. Jpn J Infect Dis 2006, 59:186-188.
20. Koraka P., Murgue B., Deparis X., Van Gorp E.C., Setiati T.E., Osterhaus A.D., et al. Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. J Med Virol 2004, 72:445-450.
21. Cardier J.E., Rivas B., Romano E., Rothman A.L., Perez-Perez C., Ochoa M., et al. Evidence of vascular damage in dengue disease: demonstration of high levels of soluble cell adhesion molecules and circulating endothelial cells. Endothelium 2006, 13:335-340.
22. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
23. Tseng C.S., Lo H.W., Teng H.C., Lo W.C., Ker C.G. Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2005, 43:99-102.
24. Sathupan P., Khongphattanayothin A., Srisai J., Srikaew K., Poovorawan Y. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection. Ann Trop Paediatr 2007, 27:179-184.
25. Srikiatkhachorn A., Ajariyakhajorn C., Endy T.P., Kalayanarooj S., Libraty D.H., Green S., et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J Virol 2007, 81:1592-1600.
26. Baugh J.A., Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-35.
27. Gando S., Nishihira J., Kobayashi S., Morimoto Y., Nanzaki S., Kemmotsu O. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 2001, 27:1187-1193.
28. Bozza F.A., Gomes R.N., Japiassu A.M., Soares M., Castro-Faria-Neto H.C., Bozza P.T., et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22:309-313.
29. Chen L.C., Lei H.Y., Liu C.C., Shiesh S.C., Chen S.H., Liu H.S., et al. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006, 74:142-147.